Latest News about VTRS
Recent news which mentions VTRS
From Benzinga
 From Benzinga
 
   Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent
   
  
  
  December 28, 2023
  From Benzinga
 
   3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts
   
  
  
  December 27, 2023
  From Benzinga
 
   A Look Into Healthcare Sector Value Stocks
   
  
  
  December 25, 2023
  From Benzinga
 From MarketWatch
 
   Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
   
  
  
  November 30, 2023
  From InvestorPlace
 
   7 Low P/E Stocks Poised to Rebound
   
  
  
  November 20, 2023
  From InvestorPlace
 
   5 Value Stocks To Watch In The Healthcare Sector
   
  
  
  November 13, 2023
  From Benzinga
 
   3 Large-Cap Stocks to Buy Trading Below Book Value
   
  
  
  November 07, 2023
  From InvestorPlace
 
   Earnings Scheduled For November 7, 2023
   
  
  
  November 07, 2023
  From Benzinga
 
   Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
   
  
  
  October 31, 2023
  From Motley Fool
 
   Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
   
  October 13, 2023
  Tickers 
   VTRS
  
  
  From Motley Fool
 
   2 Top Value Stocks to Buy in October
   
  
  
  October 08, 2023
  From Motley Fool
 
   2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
   
  
  
  October 08, 2023
  From Motley Fool
 
   Viatris makes progress on Ozempic patent challenge
   
  
  
  October 04, 2023
  From MarketWatch
 
   Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
   
  
  
  October 03, 2023
  From Benzinga
 From Benzinga
 From Benzinga
 
   Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More
   
  October 02, 2023
  Tickers 
   VTRS
  
  
  From Benzinga
 
   Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
   
  
  
  September 27, 2023
  From Benzinga
 
   Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
   
  
  
  September 26, 2023
  From Benzinga
 
   'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
   
  
  
  September 22, 2023
  From Benzinga
 From Motley Fool
 
   3 Pharmaceutical Stocks That Are Too Cheap to Ignore
   
  
  
  September 09, 2023
  From Motley Fool
 From MarketWatch
 From Motley Fool
 
   Stock market bulls are still on top
   
  
  
  August 31, 2023
  From MarketWatch
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
